Canada - engelsk - Health Canada

sterimax inc - dobutamine (dobutamine hydrochloride) - solution - 12.5mg - dobutamine (dobutamine hydrochloride) 12.5mg - selective beta 1-adrenergic agonists

Irland - engelsk - HPRA (Health Products Regulatory Authority)

claris lifesciences (uk) limited - dobutamine hydrochloride - concentrate for soln for inf - 12.5 mg/ml - adrenergic and dopaminergic agents

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

hameln pharma ltd - dobutamine hydrochloride - solution for infusion - 12.5mg/1ml

USA - engelsk - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine in 5% dextrose injection, usp is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risks of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine in 5% dextrose injection, usp is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to dobutamine or any of its components.

USA - engelsk - NLM (National Library of Medicine)

hainan poly pharm. co., ltd. - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine injection, usp is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risk of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine

USA - engelsk - NLM (National Library of Medicine)

slate run pharmaceuticals - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine injection, usp is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risk of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine hydrochloride is contraindic

USA - engelsk - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risk of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine is contraindicated in patients with idiopath

Israel - engelsk - Ministry of Health

taro international ltd, israel - dobutamine as hydrochloride - solution for infusion - dobutamine as hydrochloride 250 mg / 20 ml - dobutamine - dobutamine is indicated for patients who require a positive inotropic support in the short term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures, especially when a low cardiac output is associated with raised pulmonary pressure

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - dobutamine hydrochloride 12.5 mg/ml - solution for injection - 12.5 mg/ml - active: dobutamine hydrochloride 12.5 mg/ml excipient: sodium metabisulfite water for injection - dobutamine hydrochloride is indicated when inotropic support is necessary for the treatment of patients with hypoperfusion states in whom cardiac output is insufficient to meet circulatory demands. dobutamine hydrochloride is also indicated when inotropic support is required for the treatment of patients in whom abnormally increased ventricular filling pressures introduce the risk of pulmonary congestion and oedema. (refer to the data sheet for conditions which may precipitate such situations).

Belgien - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - dobutamine hydrochloride 14 mg/ml - eq. dobutamine 12,5 mg/ml - concentrate for solution for infusion - 250 mg/20 ml - dobutamine hydrochloride 14 mg/ml - dobutamine